BRA
BIVV

Bender Robert & Associates’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Bender Robert & Associates’s Portfolio BIVV Stock Details BIVV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-3,481
Closed -$209K – 52
2017
Q2 		$209K Sell
3,481
-830
-19% -$47.3K 0.13% 48
2017
Q1 		$235K Buy
+4,311
New +$212K 0.15% 46

Other funds holding BIVV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bender Robert & Associates's BIVV Position: Q3 2017 in Review

Bender Robert & Associates sold out of Bioverativ Inc. Common Stock (BIVV) in Q3 2017, closing a stake of 3,481 shares — an estimated $209K sold.

Bender Robert & Associates first reported a position in BIVV in Q1 2017 and held it in 2 quarters. The position peaked at $235K in Q1 2017. 446 funds tracked by Wall St. Rank hold BIVV as of Q3 2017.

  • Bender Robert & Associates reported no remaining Bioverativ Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
  • Bender Robert & Associates sold 3,481 Bioverativ Inc. Common Stock shares in Q3 2017, an estimated $209K.
  • Bender Robert & Associates first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 2 quarters.
  • Bender Robert & Associates's Bioverativ Inc. Common Stock position peaked at $235K in Q1 2017.
  • 446 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q3 2017.

Based on Bender Robert & Associates's 13F filing for Q3 2017, filed 23 Oct 2017.